Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic…
<!-- Name:DistributionId Value:8788196 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Bellicum
Bellicum Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR…
HOUSTON, Dec. 11, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced…
Bellicum Pharmaceuticals to Participate in the 2022 Cell & Gene Meeting on the…
HOUSTON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced…
Bellicum Pharmaceuticals to Participate in the B. Riley Securities 2022 Virtual…
HOUSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced…
Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global…
HOUSTON, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced…